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Summary Current evidence supports that inﬂammation is a major driving force
underlying the initiation of coronary plaques, their unstable progression, and even-
tual disruption; patients with a more pronounced vascular inﬂammatory response
have a poorer outcome.
Biomarkers are generally considered to be proteins or enzymes — measured in
serum, plasma, or blood — that provide independent diagnostic and prognostic value
by reﬂecting an underlying disease state. In the case of coronary artery disease
(CAD), inﬂammatory biomarkers, have been extensively investigated; more evidence
exists for C-reactive protein (CRP). Using high sensitivity (hs) assays, epidemiologic
data demonstrate an association between hs-CRP and risk for future cardiovascular
morbidity and mortality among those at high risk or with documented CAD. More-
over, a series of prospective studies provide consistent data documenting that mild
elevation of baseline levels of hs-CRP among apparently healthy individuals is asso-
ciated with higher long-term risk for cardiovascular events. Yet, the predictive value
of hs-CRP is found to be independent of traditional cardiovascular risk factors.
Recent studies suggest that, besides CRP, other inﬂammatory biomarkers such
as cytokines [interleukin (IL)-1, IL-6, IL-8, monocyte chemoattractant protein-
1 (MCP-1)], soluble CD40 ligand, serum amyloid A (SAA), selectins (E-selectin,
P-selectin), myeloperoxidase (MPO), matrix metalloproteinases (MMPs), cellular
adhesion molecules [intercellular adhesion molecule 1 (ICAM-1), vascular adhesion
molecule 1 (VCAM-1)], placental growth factor (PlGF) and A2 phospholipases may
have a potential role for the prediction of risk for developing CAD and may correlate
with severity of CAD.
Finally, indications suggest that the increased risk associated with inﬂammation
may be modiﬁed with certain preventive therapies and biomarkers may help to
identify the individuals who would beneﬁt most from these interventions.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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tractant cytokines, such as monocyte chemoat-
tractant protein-1 (MCP-1), mediate transmigration
of inﬂammatory cells into the subendothelial
space [9]. In addition to MCP-1, macrophage
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olony-stimulating factor (M-CSF) contributes to
he differentiation of monocytes into macrophages
10]. The concurrent uptake of low-density lipopro-
eins (LDLs) by monocyte-derived macrophages
ransforms them into the lipid-laden foam cells
hat constitute a key element of the fatty streak,
he ﬁrst recognizable progenitor of the advanced
therosclerotic lesion [11—13]. Mononuclear cells
elease cytokines, including interleukin (IL)-1 [14]
nd IL-6 [15]. Cytokine release from the fatty streak
ecruits further inﬂammatory cells (macrophages,
ast cells, activated T cells), resulting in fur-
her uptake and oxidation of LDLs. These cytokines
lso stimulate smooth muscle cell proliferation and
evelopment of a collagenous ﬁbrous cap that cov-
rs this inﬂammatory mixture [14]. This ﬁbrous
ap separates the pro-coagulant contents of the
theroma core from the circulating blood; colla-
en produced by smooth muscle cells in the lesion
rovides mechanical strength and stability to the
brous cap. The synthesis and breakdown of col-
agen is dynamically controlled by inﬂammatory
ignals [16,17].
There are data showing that the risk for an
cute coronary event has less to do with the
egree of angiographic luminal stenosis than with
he underlying pathology of the atherosclerotic
laque that makes it susceptible to rupture [17].References...........................................
Introduction
Pathophysiology of inﬂammation in
atherosclerotic plaque
There is an extensive literature supporting the
role of inﬂammation in coronary artery disease
(CAD). Inﬂammatory cells, inﬂammatory proteins,
and inﬂammatory responses from vascular cells
play a pivotal role in the pathogenesis of various
stages of atherosclerosis, including the initiation
and progression of atheroma, plaque instability
and rupture, and post-angioplasty and resteno-
sis [1—3]. The vascular endothelium is subject
to injury from numerous potential insults, such
as hemodynamic forces [4], oxidative stress [5],
and modiﬁed lipoproteins [6]. Although circulating
leukocytes do not adhere to the normal vascular
endothelium, injured endothelium expresses sev-
eral classes of adhesion molecules that selectively
bind to leukocytes [7]. Endothelial dysfunction
is marked by the up-regulation of cellular adhe-
sion molecules, such as vascular adhesion molecule
1 (VCAM-1), intercellular adhesion molecule 1
(ICAM-1), and selectins, which cooperate with
chemokines and mediate increased adhesion of
mononuclear and neutrophil leukocytes [8]. Fol-
lowing adherence to the endothelium, chemoat-ctivated T cells secrete interferon gamma (INF-)
hat decreases smooth muscle cell production of
ollagen. Activated macrophages secrete matrix
etalloproteinases (MMPs) that proteolytically
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egrade collagen, rendering the ﬁbrous cap weak
nd prone to rupture [1]. Plaque rupture permits
ontact between the pro-coagulant lipid core
nd the blood, after which further inﬂammatory
eactions lead to platelet activation, coagulation
ascade, further vasomotor dysfunction, and
ltimately luminal occlusion [1,18]. Adhesive
nteractions between vascular cells play important
oles in orchestrating the inﬂammatory response.
ecruitment of circulating leukocytes to vas-
ular endothelium requires multistep adhesive
nd signaling events including selectin-mediated
ttachment and rolling, leukocyte activation, and
ntegrin-mediated ﬁrm adhesion and diapedesis
hat result in the inﬁltration of inﬂammatory cells
nto the blood vessel wall [19]. During ﬁrm adhe-
ion of leukocytes to the endothelium, members of
he 2-integrin family, LFA-1 (CD11a/CD18, L2),
ac-1 (CD11b/CD18, M2), and p150,95 (X2),
s well as 1-integrins on the leukocyte surface,
nteract with endothelial counterligands such as
CAM-1, surface-associated ﬁbrinogen, or VCAM-1
20,21]. Interestingly, lipoprotein(a) [Lp(a)], which
s considered a risk factor for the development
f atherosclerotic disorders, seems to speciﬁcally
nteract with the 2-integrin Mac-1, through
ts apo(a) moiety Lp(a), thereby promoting the
dhesion of leucocytes and their transendothelial
igration. Yet, via its interaction with Mac-1,
p(a) induces activation of the proinﬂammatory
ranscription factor NFB, as well as the NFB-
elated expression of prothrombotic tissue factor,
uggesting the mechanism for the atherogenic
roperties of Lp(a) [22].
Percutaneous coronary intervention (PCI) pro-
uces a signiﬁcant inﬂammatory reaction in the
njured vessel wall, that may lead to the develop-
ent of neointimal thickening and restenosis [23].
alloon coronary angioplasty or stent deployment
s associated with signiﬁcant platelet activation,
hich promotes leukocyte recruitment to the
njured vessel wall [24]. There is increasing exper-
mental and clinical evidence on the molecular
echanisms that regulate the adhesion and subse-
uent trafﬁcking of leukocytes to the vessel wall
n the absence of the arterial endothelium such as
ccurs after angioplasty. Diacovo et al. [25] pro-
osed a model of leukocyte recruitment at sites
f platelet and ﬁbrin deposition in which Mac-1
s required for polymorphonuclear leukocyte dia-
edesis. Additional in vitro observations indicated
hat platelets are capable of up-regulating and
ctivating Mac-1 as a consequence of functional
esponses elicited by P-selectin on polymorphonu-
lears through P-selectin glycoprotein ligand-1
PSGL-1) signaling [26]. Inoue et al. provided con-
C
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iderable insight into the roles of Mac-1 supporting
he notion that platelets deposited at sites of
rterial injury are capable of local leukocyte inte-
rin activation in humans. They demonstrated that
CI induces activation and up-regulation of Mac-1
n the surface of neutrophils, with the maximum
esponse at 48 h after PCI, and this is associated
ith restenosis [3,27]. Oxidative burst in the post-
tent inﬂammatory process, resulting from Mac-1
ependent activation of neutrophils, probably con-
ributes to this phenomenon of lumen loss [28].
Because of the central role of inﬂammation
n atherogenesis, plaque stability and restenosis
fter PCI, several clinical studies have targeted
nﬂammatory factors as potential markers for car-
iovascular risk assessment.
he role of chronic infection in coronary
rtery disease
ecent data demonstrate that chronic infection
ay play a role in the initiation, progression, and
estabilization of atherosclerotic plaques with sev-
ral potential mechanisms. The effect may result
rom direct vessel wall colonization of the infec-
ious agent that may damage the vessel either
irectly or indirectly by initiating immunologic
esponses. Moreover, the effect may simply be the
nhancement of the pre-existing chronic inﬂam-
atory response of the body to traditional risk
actors such as hyperlipidemia. Chronic infection
ay inﬂuence pre-existing plaque by enhancing
-cell activation or other inﬂammatory responses
nd cause destabilization of the ﬁbrous cap
29]. The infectious agents with the most evi-
ence to support an etiologic relationship with
therosclerosis are Chlamydia pneumoniae (Cp)
30—33] and cytomegalovirus [32,34,35]. A variety
f other potential agents include herpes viruses
36], inﬂuenza [37,38], Mycoplasma pneumonia
31], and chronic infections with common bacte-
ial agents such as periodontal disease [39,40].
ecently, Jha et al. reported that IL-6 was sig-
iﬁcantly higher in CAD patients with more than
edium Cp IgA levels (>1.7 index number) than con-
rols without CAD. The authors hypothesized that
p IgA and elevated IL-6 may synergize to acceler-
te CAD [41].
iomarkers in coronary artery disease-reactive protein
-reactive protein (CRP) is the best studied of the
nﬂammatory biomarkers in CAD. This inﬂammatory
e
t
a
f
f
h
t
T
C
a
l
a
o
a
i
i
a
f
d
I
a
i
l
i
s
h
e
M
e
2
e
t
a
u
d
w
f
a
d
l
C
t
A
i
e
h
r
o320
biomarker has several characteristics that render it
particularly attractive. It is an acute phase protein
that has been shown to be a marker of systemic
inﬂammation, elevated in response to injury, infec-
tion, and other inﬂammatory stimuli [42]. Hepatic
production is directly related to IL-6 stimulation
and, unlike other acute phase reactants, its lev-
els remain stable over long periods in the absence
of new stimuli [43]. However, CRP is not only
a powerful inﬂammatory marker, but increasing
evidence suggests that CRP may also directly partic-
ipate in the inﬂammatory process of atherogenesis
[44,45]. Ishikawa et al. suggested CRP localization
in atherosclerotic plaque [44]. They also suggested
that CRP plays an important role on plaque vulnera-
bility and in the pathogenesis of unstable angina, as
well as restenosis after coronary intervention [44].
Similarly, Inoue et al., demonstrated CRP is pro-
duced at the site of the culprit plaque, via the exis-
tence of CRP gradient in coronary arterial blood,
sampled just distal and proximal to the culprit
lesions [45]. Yet, in the same study, the transcar-
diac CRP gradient (coronary sinus minus peripheral
blood), and activated Mac-1, increased gradually
after stenting, reaching a maximum at 48 h. Fur-
ther, there was a positive correlation between the
transcardiac CRP gradient and activated Mac-1 at
48 h. These ﬁndings suggest CRP is produced at the
site of the vulnerable plaque or the vessel wall
injured by PCI and this locally released CRP may
play a role in Mac-1 activation and restenosis [45].
In contrast to many other inﬂammatory mark-
ers, assay techniques for high sensitive (hs)-CRP are
reliable, fully automated, and sensitive, providing
a simple clinical tool for the careful assessment of
systemic inﬂammation [46]. Therefore, a statement
from the US Centers for Disease Control and Preven-
tion and the American Heart Association (CDC/AHA)
recommended that CRP has the assay character-
istics most conducive to use in clinical practice
compared with other inﬂammatory markers [47].
Circulating levels of CRP have been found to be
related to a number of well known cardiovascular
risk factors, such as obesity, smoking, blood pres-
sure, serum triglycerides, apolipoprotein B, fasting
blood glucose, heart rate, serum ﬁbrinogen and
inversely to HDL-cholesterol levels, both in children
and in adults [48,49]. Healthy individuals with at
least one of their parents with myocardial infarc-
tion (MI) had elevated CRP levels compared with
those without heredity for myocardial infarction
[50]. In a recent study, conducted on patients
with various cardiovascular risk factors but no CAD
(diabetic, hypertensive, smokers, and obese), in
addition to healthy controls, the CRP levels, age,
waist circumference, homocysteine, and triglyc-
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rides were predictors of intima-media thickness of
he carotid artery assessed by Doppler, while CRP,
ge, and triglycerides were predictors of plaque
ormation [51]. Further, a small case-control study
ound that 60 patients with chronic stable angina
ad twice median CRP levels compared with con-
rols [52].
he role of CRP for prognosis in CAD
RP levels may be useful for short-term prognosis
nd long-term risk assessment after a cardiovascu-
ar event. Therefore, several studies have looked
t associations between CRP levels and the risk
f early death or recurrent cardiac events shortly
fter an acute coronary syndrome (ACS).
Morrow et al., in the study of the Thrombosis
n Myocardial Infarction (TIMI) 11A trial, a random-
zed, dose-ranging trial of enoxaparin in unstable
ngina and non-Q wave myocardial infarction,
ound that CRP levels were higher in patients who
ied than in survivors (0.72mg/L versus 1.3mg/L).
n a substudy of TIMI 11A trial, CRP was identiﬁed
s an independent predictor of mortality at 14 days
n ACS, including those with a negative troponin
evel [53]. In another large trial, the Fragmin dur-
ng InStability in Coronary Artery Disease (FRISC)
tudy, a randomized trial of low-molecular weight
eparin in unstable coronary syndromes, CRP lev-
ls were independent predictors of cardiac death.
ortality was 5.7% among patients with CRP lev-
ls <2mg/L, 7.8% among patients with CRP levels
—10mg/L, and 16.5% among patients with CRP lev-
ls >10mg/L [54]. In the Global Use of Strategies
o open Occluded arteries IV (GUSTO-IV) substudy,
lthough hs-CRP elevation during the acute stage of
nstable CAD was associated with an increased 30-
ay mortality independent of troponin levels, there
as no association with an increased risk of non-
atal recurrent ischemic events [55]. Therefore, it
ppears that after ACS, CRP is a better predictor of
eath than nonfatal ischemic events.
Similarly, the association between CRP and a
ong-term risk assessment in patients with stable
AD or after an ACS has been efﬁciently inves-
igated. In the prospective European Concerted
ction on Thrombosis and Disabilities Study (ECAT),
t was found that among 2121 patients with angina,
ach standard deviation increase in baseline
s-CRP was associated with a 45% increase in the
elative risk (RR) of nonfatal myocardial infarction
r sudden cardiac death over 2 years of follow-up
56]. In addition, recent data also conﬁrm that
RP is a strong independent predictor of mortality
mong ACS patients who are treated with early
evascularization. In a prospective study of patients
ho underwent early invasive therapy after non-ST
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levation ACS, CRP >10mg/L during admission
emained associated with increased risk of death
ver a follow-up of 20 months [57]. Yet, in 319
atients with acute MI treated with thrombolytic
herapy, it was found that patients with CRP levels
n the highest tertile had a lower incidence of
eperfusion and a greater in-hospital mortality [58].
RP and MI
t has been shown that CRP levels are associated
ith the size of the infarct [59]. In addition, it was
uggested that in patients with acute MI, CRP levels
orrelate with the presence of plaque rupture, as
ssessed by intravascular ultrasound [60]. Further,
n increased temperature at unstable coronary
laques, evaluated by the invasive thermogenetic
atheter, has been shown to be related to CRP lev-
ls [61]. Consequently, it was suggested that CRP
n the acute phase of MI could be correlated with
isk assessment. However, a prospective study of
360 patients with unstable or stable angina pec-
oris or acute MI found that adjusted hazard ratios
or death/acute MI for CRP levels above the ﬁrst
ertile showed a signiﬁcant risk of 1.8 with stable
ngina, 2.7 for unstable angina, and only 1.0 for
cute MI [62]. On the contrary, in stable post-MI
atients, elevated hs-CRP predicted a signiﬁcantly
igher risk for recurrent nonfatal MI or fatal coro-
ary events (75% higher in the highest versus lowest
uintile of hs-CRP), suggesting that CRP is not only a
arker for the extent of myocardial damage [63].
ased on these data, one could suppose that CRP
evels are predictive of short- and long-term cardiac
vents in patients with stable and unstable angina,
ut may not be predictive in the acute stage of MI.
herefore, the measurements should be delayed
ntil the acute phase reaction is over and levels
ave returned to baseline.
Nevertheless, the results are not homogenous
ven in the case of stable MI. The Thrombogenic
actors and Recurrent Coronary Events (THROMBO)
tudy was a multicenter investigation of 1045 post-
I patients that measured CRP levels 2 months after
he event and again at 2 years. Although CRP levels
ere found to be associated with recurrent coro-
ary events, in multivariable analyses, CRP was not
roved to be an independent marker for recurrent
oronary events [64].
RP and primary prevention
everal prospective studies in apparently healthy
ndividuals have shown that elevated hs-CRP lev-
ls are correlated with higher risk for future
ardiovascular morbidity and mortality. The Mul-
iple Risk Factor Interventional Trial (MRFIT), a
ested case-control study, found that increased CRP
e
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evels predicted increased risk of cardiovascular
isease in middle-aged men, but this relationship
as statistically signiﬁcant only for smokers [65].
he Physicians’ Health Study (PHS), a prospective,
ested, case-control study of men who did not
ave prior history of cardiovascular disease and
ad low rates of cigarette use, showed that those
ith highest baseline levels of hs-CRP had two
imes the risk of future stroke, three times the risk
f future MI, and four times the risk to develop
evere peripheral arterial disease. Cardiovascular
isks were not inﬂuenced by smoking status, and
ere independent of lipid or other cardiovascu-
ar factors [66]. Data from European Monitoring
rends and Determinants of Cardiovascular Disease
MONICA)-Augsburg prospective study offer consis-
ent observations regarding the prognostic capacity
f hs-CRP among individuals without clinical evi-
ence of CAD. This study followed 936 healthy,
iddle-aged men over 8 years and noted a 19%
ncrease in risk for future nonfatal or fatal coro-
ary events for each standard deviation increase in
aseline hs-CRP after adjustment for multiple risk
actors, including smoking status [67].
Recently, in the prospective Prevention of Renal
nd Vascular Endstage Disease (PREVEND) study,
139 individuals without previous documented
oronary artery disease were followed for the inci-
ence of coronary angiography and coronary events
rom 1997 to 2003. hs-CRP levels were found to
e associated with angiographic characteristics and
linical consequences of plaque instability during
ollow-up [68].
The Women’s Health Study (WHS), a prospec-
ive nested case-control study of postmenopausal
omen showed that hs-CRP was the most power-
ul predictor of cardiovascular risk compared with
ther inﬂammatory markers, baseline lipid levels,
nd homocysteine. Women who developed cardio-
ascular events had higher baseline levels of CRP
han control subjects; yet, those in the highest
uartile of CRP had a relative risk of 4.4 of any
ardiovascular event compared with those in the
owest quartile. A subgroup analysis of women with
DL levels of <130mg/dL, a group traditionally con-
idered to be low risk, found that those who had
levated baseline CRP were at higher risk for future
vents. A follow-up study of the entire cohort
howed that CRP levels were stronger predictors of
ardiovascular events than LDL cholesterol [69,70].
It appears that among healthy men and women,levated CRP levels predict risk of a ﬁrst cardiovas-
ular event independently of other factors. Based
n PHS [66] and WHS [69], the adjusted relative risk
f a future cardiovascular event increases 26% for
en and 33% for women overall for each quartile
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increase in hs-CRP levels [71]. Therefore, data sug-
gest that hs-CRP levels add to risk prediction based
on lipid parameters, and may be useful for identify-
ing patients at risk for future cardiovascular events
who would have been classiﬁed as low risk.
Finally, a recent study showed that hs-CRP may
be a useful marker in screening the children who
are at risk of CAD in adulthood. The levels of hs-CRP
were measured in 51 children (11.79± 3.14 years)
with risk factors for CAD (hypercholesterolemia,
hypertension, obesity, low HDL-cholesterol, and
familial history of CAD). The results were compared
with 26 children (12.98± 2.59 years) without any
risk factors. The children with risk factors had sig-
niﬁcantly higher levels of hs-CRP compared to the
control group (P < 0.01). The concentrations of CRP
were signiﬁcantly increased in children with three
or more risk factors [72]. Early identiﬁcation of
the children with risk factors and interventions for
obesity, harmful habits, and life style in childhood
might decrease the incidence of coronary heart dis-
ease in adulthood.
CRP and preventive therapies
Apart from providing global risk prediction, CRP
screening may also provide a method of targeting
preventive interventions. In vitro and in vivo studies
show that CRP is not only an indicator of inﬂamma-
tion, but also contributes to plaque development,
plaque instability, and thrombus formation [73,74].
Therefore, the relationship between certain cardio-
protective medications, such as statin and aspirin
therapy, and CRP levels has been examined.
Studies have shown that statin therapy lowers
CRP levels independently of lipid levels, supporting
the possibility that statins have anti-inﬂammatory
effects. Data from the Cholesterol And Recurrent
Events (CARE) study, a randomized trial of pravas-
tatin in post-MI patients, revealed that although
the risk of recurrent coronary events was reduced
by therapy with pravastatin among individuals with
and without evidence of inﬂammation, the relative
risk reduction was greater for those with consistent
evidence of inﬂammation (54% versus 25%) even
though the lipid proﬁles were similar in both groups
[63]. This information suggests that statin therapy
may be particularly effective among patients with
elevated CRP levels. PRavastatin Or atorVastatin
Evaluation and Infection Therapy (PROVE-IT) trial
demonstrated that intensive statin therapy that
lowered hs-CRP levels to a mean of less than 2mg/L
resulted in a reduction risk for recurrent MI or fatal
coronary event, irrespective of the degree of LDL
lowering [75].
In the PRavastatin Inﬂammation CRP Evalua-
tion (PRINCE) study, pravastatin reduced hs-CRP
i
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evels in subjects without prior history of cardio-
ascular disease [76]. A further analysis of the Air
orce/Texas Coronary Atherosclerosis Prevention
tudy (AFCAPS/TexCAPS) has extended the observa-
ion that statin therapy directly lowers CRP levels
s primary prevention. Subjects with average lev-
ls of total cholesterol and below-average levels of
DL-cholesterol were divided into groups accord-
ng to median levels of LDL cholesterol and CRP.
hose with elevated LDL (above median value)
ere at increased risk for future cardiovascular
vents and beneﬁted substantially from random-
zation to lovastatin, irrespective of CRP level.
hose with low LDL and low CRP (below median
alues) were at low risk and derived little ben-
ﬁt from lovastatin therapy. Those with low LDL
below median value) but high CRP (above median
alue) were at increased risk and derived substan-
ial beneﬁt from lovastatin therapy [77]. Recently,
he results from the Justiﬁcation for the Use of
tatins in Prevention: an Intervention Trial Evalu-
ting Rosuvastatin (JUPITER) were reported [78].
UPITER, was a randomized, double-blind, placebo-
ontrolled, multicenter trial which assigned 17802
pparently healthy men and women with low LDL
evels (less than 130mg/dL) but hs-CRP of 2mg/L
r higher to receive rosuvastatin 20mg daily or
lacebo, in order to assess the incidence of a
rst major cardiovascular event. The subjects were
ollowed up for a median of 1.9 years (maxi-
um, 5.0). Rosuvastatin reduced LDL cholesterol
evels by 50% and hs-CRP by 37%. The rates of
he primary end point were 0.77 and 1.36 per
00 person-years of follow-up in the rosuvastatin
nd placebo groups, respectively (hazard ratio for
osuvastatin, 0.56; 95% conﬁdence interval [CI],
.46—0.69; P < 0.00001), with corresponding rates
f 0.17 and 0.37 for MI (hazard ratio, 0.46; 95%
I, 0.30—0.70; P = 0.0002), 0.18 and 0.34 for stroke
hazard ratio, 0.52; 95% CI, 0.34—0.79; P = 0.002),
.41 and 0.77 for revascularization or unstable
ngina (hazard ratio, 0.53; 95% CI, 0.40—0.70;
< 0.00001), and 0.45 and 0.85 for the combined
nd point of MI, stroke, or death from cardiovascu-
ar causes (hazard ratio, 0.53; 95% CI, 0.40—0.69;
< 0.00001). The authors concluded that rosuvas-
atin signiﬁcantly reduced the incidence of major
ardiovascular events in apparently healthy persons
ithout hyperlipidemia but with elevated hs-CRP
evels [78]. These studies provide evidence for the
on-lipid effects of statins and suggest that test-
ng for CRP may identify many subjects, who are
ot eligible for statin therapy based on LDL levels,
ut are at high risk for future cardiovascular events
nd might beneﬁt from statin therapy. Therefore,
RP levels may provide a method for targeting
Inﬂammatory biomarkers in coronary artery disease
Table 1 Factors affecting serum CRP levels.
Increased levels Decreased levels
Increased blood pressure Moderate alcohol
consumption
Increased body mass
index
Increased
activity/endurance
exercise
Metabolic
syndrome/diabetes
mellitus
Weight loss
Low HDL/high
triglycerides
Medications;
statins—ﬁbrates—niacin
Estrogen/progestogen
use
? ACE inhibitors-?
Aspirin
Chronic infections
(gingivitis, bronchitis)
Chronic inﬂammation
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strated an association between MCP-1 levels and(rheumatoid arthritis)
Modiﬁed from Pearson et al. [47].
tatin therapy in primary and secondary preven-
ion.
In the PHS, use of aspirin was associated with
statistically signiﬁcant (55.7%) risk reduction for
uture MI among men who had hs-CRP levels in the
ighest quartile and with a nonsigniﬁcant (13.9%)
eduction among those who had hs-CRP levels in
he lowest quartile [66]. However, only few data
re available regarding the direct effect of aspirin
n CRP levels. A small randomized trial of low-dose
spirin in healthy volunteers, found that aspirin had
o detectable effect on CRP [79].
Finally, the CDC/AHA statement contains rec-
mmendations for the use of CRP in the diagnosis
nd management of cardiovascular disease [47].
he authors recommend two separate CRP mea-
urements, preferably 2 weeks apart. Yet, the
DC/AHA statement suggests use of hs-CRP for risk
ssessment in patients who are at intermediate
isk for cardiovascular events (10—20% 10-year risk
f coronary event) and classiﬁes hs-CRP levels of
1.0mg/L as low risk, 1—3mg/L as average risk,
nd >3.0mg/L as high risk. A CRP level greater
han 10mg/L indicates the presence of a signif-
cant acute phase response; usually indicates a
oncardiovascular source of inﬂammation, and fur-
her assessment is required to determine the cause
47]. (Table 1 indicates certain patient characteris-
ics and conditions that have been associated with
ncreased or decreased CRP levels.) Therefore, the
uthors indicate the measurement of CRP for iden-
ifying patients without known CAD who may be at
higher risk than estimated by traditional risk fac-
ors. However, they suggest that further data from
rospective clinical trials are needed to determine
t
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f patients with only elevated CRP levels should be
reated [47].
ytokines
ytokines include a number of pleiotropic proteins
hat have been extensively implicated in the pro-
ess of inﬂammation. Among the main cytokines are
L-1, IL-6, IL-10, tumor necrosis factor alpha (TNF-
), and MCP-1 [9,14,15]. IL-1 and IL-6 drive produc-
ion of reactant proteins, including CRP. IL-6 may
ncrease plaque instability driving expression of
atrix metalloproteinases, TNF-, and MCP-1 [80].
Elevated IL-6 levels in healthy men correlated
ith increased risk for future MI independently of
s-CRP [81]. Recently, a case-control study of 294
atients with clinically stable ACS (group I) and clin-
cally stable angina pectoris (group II), showed that
edian IL-6 levels were signiﬁcantly higher in group
than in group II (P < 0.05) [82]. In the Fragmin
nd/or early Revascularization during InStability in
oronary artery disease (FRISC-II) study, elevated
L-6 (>5 ng/L) was associated with higher 6- and
2-month mortality, independent of troponin and
s-CRP [83]. In this study patients with high IL-
had a greater response to an invasive versus
onservative strategy than patients with low IL-6
evels. These data suggest that elevated IL-6 lev-
ls may identify patients with more severe events,
ho would beneﬁt from more aggressive treatment.
owever, the application of IL-6 as a biomarker is
imited by large circadian variations and lack of
onﬁrmatory studies.
It has been shown that plasma concentrations
f IL-1 are elevated in patients with hypercholes-
erolemia [84]. It seems that statin therapy may
ower IL-1 levels in these patients [85]. However,
urther data from clinical studies are needed for
ssessment of the relationship between IL-1 and
therosclerotic clinical events.
TNF- has been implicated in myocardial dys-
unction and remodelling after acute coronary
vents [86]. In the CARE study, recurrent coronary
vents after a MI were associated with higher TNF-
evels compared with controls [87].
MCP-1, as already mentioned, is a chemokine
hat helps recruit monocytes into the arterial
ntima and activates these cells to promote
therosclerosis [9,88]. As assessed by coronary
ngiogram, measurements of MCP-1 in the coronary
lood of patients with unstable angina demon-he extent of coronary atherosclerosis [89]. In the
rboﬁban in Patients with Unstable coronary Syn-
romes (OPUS)-TIMI 16 trial, MCP-1 levels above the
5th percentile (238 pg/mL) were associated with
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an increased risk of death or MI after 10 months,
even after adjustment for traditional risk fac-
tors [90]. However, although MCP-1 is a promising
biomarker, further research is needed to evaluate
its clinical utility.
IL-10 mediates anti-atherogenic pathways. In the
c7E3 AntiPlatelet Therapy in Unstable REfractory
angina (CAPTURE) study, patients with elevated IL-
10 levels had a decreased risk of death or nonfatal
MI. Yet, those with elevated CRP and IL-10 were at
lower risk than those with elevated CRP only [91].
These data suggest that IL-10 may be protective
against proinﬂammatory mediators in ACS.
To make things more confused, in a recent
study, 158 consecutive patients with angiographi-
cally identiﬁed stable CAD were enrolled. Plasma
levels of the following 10 cytokines were measured:
IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-,
granulocyte-macrophage colony-stimulating factor
(GM-CSF), and IFN-. The multivariate analysis
using multi-vessel disease, diabetes, and the levels
of all 10 cytokines and hs-CRP showed that the only
independent predictor of cardiovascular events was
IL-8 (RR, 2.98; 95% CI, 1.64—7.24; P = 0.0001), dur-
ing a 7-year follow-up period [92]. These data, in
fact, suggest that the role of cytokines in the pre-
diction of cardiovascular risk is still controversial,
or, at least, we do not know yet, which one is better
as a prognostic biomarker and probably a therapeu-
tic target in CAD.
Soluble CD40 ligand
Soluble CD40 ligand (sCD40L) is a proinﬂammatory
marker that has been shown to promote atheroscle-
rosis and plaque instability [93]. Healthy women
with high levels of sCD40L have been shown to be
at increased risk for cardiovascular events [94]. In
the CAPTURE trial, patients with elevated sCD40L
(>5g/L) were at increased 6-month risk of death
or nonfatal MI. Treatment of these patients with
abciximab before coronary angioplasty reduced the
risk. This beneﬁt was observed in patients with
and without troponin elevation, and no beneﬁt
of abciximab was observed in patients with ele-
vated troponin values but low sCD40L values [95].
The investigators of the CAPTURE trial concluded
that sCD40L may be an independent risk marker of
cardiovascular events and a marker for determin-
ing beneﬁt from therapy with glycoprotein IIb/IIIa
inhibitors. Similarly, a substudy of the OPUS-TIMI
16 trial showed that patients with sCD40L levels
above the median value were at an increased risk
for death or recurrent MI and that sCD40L provided
prognostic ability independent of troponin I and CRP
[96].
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Finally, a recent study of 96 patients with ST-
egment elevation myocardial infarction showed
hat serum ratio of sCD40L/IL-10 was a better inde-
endent predictor of in-hospital adverse events
han individual sCD40L and IL-10 measurements in
hese patients [97].
erum amyloid A
erum amyloid A (SAA), like CRP, is an acute phase
rotein. In a substudy of TIMI 11A, elevated SAA
evels predicted increased risk of 14-day mortal-
ty in patients with ACS [98]. In the Women’s
schemia Syndrome Evaluation (WISE) study of
omen referred for coronary angiography because
f suspected ischemia, elevated SAA values were
orrelated with angiographic severity of CAD and
-year risk for cardiovascular events [99].
However, the results were not similar in the
hrombogenic Factors and Recurrent Coronary
vents study; the measurement of SAA levels, 2
onths after MI did not show signiﬁcant association
etween SAA levels and risk of recurrent cardiovas-
ular events over 2 years [64].
dhesion molecules
ell adhesion molecules (CAMs) and their counter
eceptors of the 2-integrin family, mainly Mac-1,
lay a pivotal role in the interactions between leu-
ocytes, platelets, and vascular endothelium [8].
dherence of circulating leukocytes to the endothe-
ium and their transmigration into the arterial wall
s an early step of atherosclerosis [8]. Soluble CAMs
sCAMs: sICAM-1, sVCAM-1 and E- and P-selectins)
re shed from cell surfaces and reﬂect cellular acti-
ation [100]. Soluble CAMs have been studied in the
arly diagnosis of ACS and in risk stratiﬁcation in
AD.
Hollander et al. considered that markers of
latelet aggregation may detect ACS earlier than
ardiac markers as plaque rupture/platelet aggre-
ation precedes myocardial ischemia. However,
lthough theoretically attractive, creatinine kinase
B fraction had a higher speciﬁcity for detection
f acute MI, ACS, and serious cardiac events, upon
mergency department arrival, than both soluble
nd membrane-bound P-selectin [101].
Mulvihill et al. measured CAMs in patients with
CS (unstable angina and non-Q MI) at presenta-
ion and then after 3, 6, and 12 months. CAMs
evels increased within 10 h of chest pain onset and
emained elevated for up to 6 months, suggesting
hat the inﬂammatory stimulus triggering expres-
ion of CAMs is long sustained, returning gradually
oward control values [102].
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In the WHS, elevated P-selectin levels in healthy
omen were associated with increased cardiovas-
ular risk [103]. However, the role of CAMs in risk
tratiﬁcation in patients with CAD is not established
s the results on predicting cardiovascular risk are
ather confusing.
In a prospective study, among patients with
table angiographically documented CAD, CAMs
sICAM-1, sVCAM-1, and E-selectin) were measured,
nd follow-up information on cardiovascular events
as obtained for a mean of 2.7 years. Although all
AMs were higher in patients with future death, in a
odel that simultaneously controlled for all inﬂam-
atory and soluble adhesion markers determined,
nly sVCAM-1 remained independently signiﬁcant
or future fatal cardiovascular events, with a 2.8-
old increase in risk. Especially sVCAM-1 added
o the predictive value of classic risk factors and
s-CRP in determining the risk of death from car-
iovascular causes [104].
In a prospective observational study, among
atients presenting acutely with ACS (unstable
ngina and non-Q MI) raised concentrations of
VCAM-1 and CRP — but not sICAM-1, E-selectin,
nd P-selectin — were predictive of an increased
ajor cardiovascular event within 6 months after
resentation. The sensitivity of CRP >3mg/L and
VCAM-1 >780 ng/mL for predicting future events
as >90% [105]. Similarly, patients with ACS pre-
ented with increased levels of sVCAM-1 compared
ith patients with stable angina or healthy indi-
iduals; moreover, those with in-hospital adverse
oronary events had elevated sVCAM-1 levels inde-
endently of CRP levels [106]. In patients with
nstable angina undergoing coronary stenting, CRP
nd sICAM-1 — but not sVCAM-1 — proved useful for
dentifying those at higher risk of a cardiac event;
et, it was suggested that CRP may play a direct
ole in promoting the inﬂammatory component of
therosclerosis by inducing signiﬁcant expression
f sICAM-1 [107]. However, a prospective study of
atients presenting to the emergency department
ith chest pain, failed to reveal any association
etween sICAM-1 and the risk of a serious cardio-
ascular event during hospital admission [108]. To
ake things more confused, Hillis et al. studied
26 consecutive patients presenting with clinical
yocardial ischemia. In this study, only P-selectin
nd cardiac troponin I — but not sICAM-1, sVCAM-
, or E-selectin — were signiﬁcantly higher among
atients who had a serious cardiac event during the
ndex admission or the subsequent 3 months. More-
ver, both remained independently predictive in a
ultivariable regression equation [109].
Mac-1 expression on the surface of polymor-
honuclear leucocytes is up-regulated after balloon
b
d
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ngioplasty and coronary stenting. The maximum
p-regulation of Mac-1, which is observed 48 h after
CI activation, is an early and robust predictor of
ate lumen loss [3,27]. Therefore, assessing the
xpression levels of integrin Mac-1 after coronary
tenting may prove helpful in predicting risk of
estenosis.
In conclusion, the utility of CAMs in predicting
he outcome of individual patients seems to be lim-
ted. More prospective studies are needed for the
tudy of secondary prevention. The counter recep-
or of CAMs, integrin Mac-1, may prove useful to
redict restenosis after PCI.
yeloperoxidase
yeloperoxidase (MPO) is a heme protein produced
y activated neutrophils, monocytes, and tissue
acrophages, and catalyzes the modiﬁcation of LDL
hich is a critical step in atherogenesis [110].
Several studies have suggested that there is an
ssociation between MPO levels and CAD [110]. In
prospective study of patients presenting to the
mergency department with chest pain, elevated
PO levels identiﬁed patients with undetectable
roponin T (TnT) levels who were at increased risk
f MI during their hospital stay or after discharge
111]. According to this information, MPO may be
seful for early risk stratiﬁcation of patients with
hest pain and non-ST elevation MI. In another well
esigned prospective study among patients with
CS, those with elevated MPO levels had a sta-
istically signiﬁcant increase in death or nonfatal
ardiovascular events at 72 h, 30 days, and 6 months
112]; moreover, MPO levels were independent of
nT, CRP, and sCD40L levels, suggesting that MPO is
n independent predictor of risk in CAD.
Finally, in the prospective European Prospective
nvestigation into Cancer and Nutrition (EPIC)-
orfolk population study, serum MPO levels were
ssociated with the future risk of coronary artery
isease, in apparently healthy individuals [113].
atrix metalloproteinases
atrix metalloproteinases are endoproteases that
re regulators of the extracellular matrix. They
re localized at the shoulder of the plaque, have
ollagenase and/or gelatinase activity, and partici-
ate in vascular remodelling and plaque instability
114,115].There are not many data for the association
etween MMPs and the prognosis of cardiovascular
isease. Peripheral blood levels of MMP-1, MMP-2,
nd MMP-9 are elevated in patients with ACS [116].
et, in patients with either stable or unstable CAD,
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those with elevated MMP-9 levels were at increased
risk for future cardiovascular death [117]. A recent
study enrolling 909 patients with acute MI, 466
patients with stable angina, and 1023 healthy older
control subjects, showed that circulating levels of
MMP-2 and MMP-9 were independently associated
with the development of an acute MI rather than
stable angina, as the initial clinical presentation of
coronary artery disease [118]. In another study, ele-
vations in MMP-1 at 7 and 14 days after ACS were
negatively correlated with left ventricular ejection
fraction [119]. However, the application of MMPs
as biomarkers is limited because of the slow eleva-
tion of MMP levels after ACS and, in fact, lack of
signiﬁcant clinical studies, as yet.
Placental growth factor
Placental growth factor (PlGF) is a member of a
family of platelet-derived proteins that function as
chemoattractants for monocytes and is involved in
the regulation of vascular endothelial growth [120].
PlGF appears to be stable in the circulation and may
prove a strong candidate as a biomarker for plaque
instability, myocardial ischemia, and prognosis for
patients with ACS.
In the CAPTURE study, patients presenting to
the emergency department with ACS had elevated
PlGF levels compared with patients with noncardiac
chest pain or stable angina. Between patients with
unstable angina and NSTEMI there was no difference
in PlGF concentrations. PlGF levels >27.0 ng/L were
associated with increased risk of death or nonfa-
tal MI at 72 h. Moreover, PlGF provided prognostic
value independently of the levels of CRP, sCD40L,
and cardiac TnT and identiﬁed a group of patients
without elevated sCD40L or cardiac TnT that were
at increased 30-day risk for a cardiovascular event
[121].
A2 phospholipases
Lipoprotein-associated phospholipase A(2) [Lp-
PLA(2)], a member of the phospholipase superfam-
ily, seems to be a highly active enzyme in the
circulation; it is also known as platelet-activating
factor acetylhydrolase. Lp-PLA(2) participates in
the oxidative modiﬁcation of LDL by cleaving oxi-
dized phosphatidylcholines, generating lysophos-
phatidylcholine and oxidized free fatty acids [122].
Recent reports indicate that Lp-PLA(2) has a dis-
tinct role in atherogenesis. Seminal ﬁndings support
further the potentially damaging role that in situ
release of LDL-associated oxidative products by Lp-
PLA(2) may have in the formation of arterial wall
lesions [123]. Local production of Lp-PLA(2) and
(
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ysophosphatidylcholine, the active product of Lp-
LA(2), in the coronary circulation were associated
ith early coronary atherosclerosis and endothelial
ysfunction in humans [124].
Investigators measured Lp-PLA(2) in 3766
atients with stable coronary artery disease, that
ere followed for a median of 4.8 years for adverse
ardiovascular events. In these patients, an ele-
ated level of Lp-PLA(2) was a signiﬁcant predictor
f nonfatal adverse cardiovascular outcomes
ndependent of traditional clinical risk factors and
s-CRP [125]. Similarly, in another study of 2513
atients with and 719 patients without angiograph-
cally conﬁrmed CAD, Lp-PLA(2) predicted risk for
-year cardiac mortality independently from estab-
ished risk factors and hs-CRP concentrations [126].
A nested case-control analysis of the WHS, the
bility of Lp-PLA(2) to predict the risk of car-
iovascular events was not statistically signiﬁcant
fter adjustment for traditional risk factors [127].
owever, in a higher risk population of men with
yperlipidemia, in the West of Scotland Coronary
revention Study (WOSCOPS), increased Lp-PLA(2)
evels predicted risk for cardiovascular events inde-
endently of other inﬂammatory markers, such as
RP. A 60% statistically signiﬁcant increase in risk
etween the highest and the lowest quintile of Lp-
LA(2) was found [128]. Yet, in the Atherosclerosis
isk in Communities (ARIC) study, Lp-PLA(2) was
ndependently associated with CAD, in patients who
ad LDL levels <130mg/dL [129]. This ﬁnding sug-
ests that Lp-PLA(2) may have a prognostic role,
imilar to CRP, in identifying high-risk patients who
ay beneﬁt from statin therapy and are not tar-
eted on the basis of LDL levels. Finally, a recent
tudy found that Lp-PLA(2) levels were associated
ith the extent of angiographic CAD, but they were
ot independently predictive after adjustment for
RP, lipid status, and other traditional risk factors
130]. In the more general setting of population
tudies, however, it is clear that Lp-PLA(2) is a pos-
tive risk factor for CAD and measurements of its
ass may contribute to the prediction of coronary
eart disease risk, especially in individuals with low
DL cholesterol levels.
Besides Lp-PLA(2), secretory type-II phospholi-
ase A(2) [sPLA(2)-II], is also a member of the
hospholipase superfamily, appearing to be an
mportant inﬂammatory mediator and biomarker of
ardiovascular disease [131]. An analysis of patients
rom the Global Registry of Acute Coronary Events
GRACE) study showed that elevated sPLA(2)-II lev-
ls were associated with increased risk of death or
I, independent of other risk factors [132].
Local activity of sPLA(2)-II in the atheroscle-
otic plaque seems to facilitate an inﬂammatory
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esponse to induce plaque instability or rupture.
n a recent study, Nijmeijer et al. studied his-
ologically the presence of sPLA(2)-II in culprit
esions in the coronary arteries of patients with
MI or stable or unstable angina, using directed
oronary atherectomy. Extracellular sPLA(2)-II was
ore abundantly present in atherosclerotic culprit
esions that had led to AMI, than in patients with
table or unstable angina [133]. This suggests a role
or extracellular sPLA(2)-II in the development of
omplications of atherosclerotic lesions in coronary
rteries.
In humans, the weight of evidence suggests that
p-PLA(2) and sPLA(2)-II are positive risk factors for
oronary heart disease — an observation commen-
urate with their position in the direct pathological
equence leading from formation of oxidized LDL in
he artery wall to cellular dysfunction and forma-
ion of lesions.
yeloid-related protein 8/14 complex
yeloid-related protein 8/14 complex (MRP8/14),
lso termed calprotectin, is a heterodimer of two
alcium binding proteins (S100A8 and S100A9, also
eferred to as MRP8 and MRP14, or calgranulin
and B) involved in calcium-dependent signal-
ng, cell differentiation, cell cycle progression, and
ytoskeleton—membrane interactions [134]. MRP8
nd MRP14 are mainly expressed in monocytes
nd neutrophils [135]. Upon phagocyte activa-
ion, MRP8 and MRP14 form the MRP8/14 complex,
hich translocates to the cytoskeleton and plasma
embrane, where it is secreted [136]. There-
ore, complex MRP8/14 constitutes a marker of
hagocyte activation, which is involved in plaque
estabilization [137]. Elevated serum levels of
RP8/14 are a useful biomarker of disease activ-
ty in inﬂammatory disorders, such as rheumatoid
rthritis and Crohn’s disease [138].
Healy et al. found increased expression of
latelet CD69 and MRP14 in STEMI patients at the
RNA level in patients presenting to the cardiac
atheterization laboratory with STEMI than patients
ith stable CAD [139]. This led the investigators to
uantify plasma protein levels of the most abun-
ant form of MRP14, the MRP8/14. Plasma levels of
RP8/14 heterodimer were higher in STEMI patients
17.0 g/mL versus 8.0 g/mL, P < 0.001) [139]. Yet,
ealthy women in the validation study [140], who
ubsequently developed cardiovascular events dur-
ng follow-up, had higher median MRP8/14 levels at
aseline than women who remained free of disease
controls, P < 0.001). In addition, in matched-pair
nalysis that accounted for age and smoking status,
he risk of a ﬁrst cardiovascular event increased sig-
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iﬁcantly with each increasing quartile of baseline
oncentration of MRP8/14 (P trend <0.001), such
hat the women in the highest versus lowest quar-
ile had 3.8-fold elevation in risk (P < 0.001). Risks
ere independent of traditional cardiovascular risk
actors and CRP.
To illustrate the potential ability of MRP8/14 to
dd prognostic value to lipid- or CRP-based screen-
ng, Healy et al. computed the relative risk of
ardiovascular events after study participants were
tratiﬁed into nine groups according to tertiles of
RP8/14 and tertiles of total cholesterol (TC):HDL
r CRP. Women with low TC:HDL or CRP and low
evels of MRP8/14 had the lowest RR. In contrast,
omen with high TC:HDL or CRP and high levels
f MRP8/14 had the highest RR [139]. Importantly,
ven among women with low or intermediate
C:HDL or CRP levels, the risk of cardiovascular
vents was greater among those with high than with
ower levels of MRP8/14 [139].
Altwegg et al. suggested that MRP8/14 that is
xpressed by monocytes and neutrophils, which
re activated in plaque destabilization, might be
levated in ACS. Therefore, they compared cir-
ulating levels of MRP8/14 in patients with ACS,
table CAD, or normal coronary arteries. Systemic
evels of MRP8/14 were markedly elevated [15.1
12.1—21.8) mg/L, P = 0.001] in ACS when compared
ith stable CAD [4.6 (3.5—7.1) mg/L] or normals
4.8 (4.0—6.3) mg/L]. In addition, MRP8/14 was
ncreased prior to necrosis markers such as myo-
lobin, CK-MB, and troponin, while using a cut-off
evel of 8mg/L, MRP8/14 identiﬁed ACS presenting
ithin 3 h from symptom onset [141].
In conclusion, the data suggest that MRP8/14
eterodimer can independently predict risk of
uture cardiovascular events and may add prog-
ostic information to that conveyed by standard
isk factors and CRP. Yet, the occurrence of ele-
ated MRP8/14 in the systemic circulation prior to
arkers of myocardial necrosis is advantageous and
akes it a prime candidate for the detection and
anagement of ACS. Obviously, further studies are
equired to elucidate the full prognostic potential
f MRP8/14 in healthy patients, as the only trial
n primary prevention was conducted in apparently
ealthy postmenopausal women followed up in the
HS [140], as well as the diagnostic and prognostic
mplications in patients with chest pain.onclusions
dvances in understanding the pathobiology of
therosclerosis have implicated inﬂammation as a
entral contributor to the initiation and progression
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of atherosclerotic vascular disease. Inﬂammatory
biomarkers may have prognostic value for future
cardiovascular risk among those at high risk or
with documented cardiovascular disease. They also
may be useful for identifying apparently healthy
individuals, without known CAD, who may be at
a higher risk than estimated by traditional risk
factors. Finally, they might help to identify the sub-
jects who are not eligible for preventive therapies
based on traditional risk factors, but are at high risk
for future cardiovascular events and might beneﬁt
most from these interventions.
However, until now, the data are conﬂicting
about which biomarker is more suitable for diagno-
sis or prognosis of CAD. Probably, a combination of
biomarkers may prove appropriate for our target.
Key points
• The role of inﬂammation in atherosclerotic
plaque is crucial.
• High sensitivity CRP is the most extensively stud-
ied biomarker of evolving coronary atheroscle-
rosis. Its measurement has been proposed as an
adjunct to established risk factors to assess the
risk for CAD.
• A cut-off level of hs-CRP of 2 (1—3) mg/L seems
to discriminate high- from low-risk patients with
stable or unstable coronary disease (ACS) or even
apparently healthy individuals for short- and
long-term prognosis of cardiovascular events.
However, the measurement of hs-CRP should be
delayed in the acute stage of MI until levels have
returned to baseline.
• Intensive statin therapy lowers lipid and CRP
levels. The signiﬁcant lessening of hs-CRP value
after an ACS reduces the risk for recurrent MI or
fatal coronary event, irrespective of the degree
of LDL lowering.
• Statins (lovastatin or rosuvastatin) reduce the
incidence of major cardiovascular events even
in apparently healthy persons without hyperlipi-
demia but with elevated hs-CRP levels. Once
more, a target value of hs-CRP of less than 2mg/L
is suggested with preventive therapies.
• Cytokines (IL-1, IL-1, IL-6, IL-8, TNF-, and MCP-
1), lipoprotein-associated phospholipase A(2)
[Lp-Pla(2)], GM-CSF, sCD40L, serum amyloid A,
soluble CAMs (sICAM-1, sVCAM-1, E- and P-
selectins), and their counter receptors (primarily
Mac-1), myeloperoxidase, matrix metallopro-
teinases (mainly MMP-9) and placental growth
factor (PlGF) have all been implicated in the
progression of plaque instability and have been
considered to add prognostic information to thatE. Zakynthinos, N. Pappa
conveyed by standard risk factors and CRP in
primary and secondary prevention of future car-
diovascular events or even restenosis (Mac-1)
after PCI.
Complex MRP8/14 heterodimer, constituting a
marker of phagocyte activation, seems to add
prognostic value to lipid-based screening of
future CAD events. Yet, using a cut-off level of
8mg/L, MRP8/14 identiﬁes ACS presenting within
3 h from symptom onset, prior to markers of
myocardial necrosis.
The predictive value of biomarkers is additive
and beyond that of CRP suggesting the need for a
‘‘multimarker approach’’ in assessing cardiovas-
cular risk.
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